MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications

More than 50 subtypes of B-cell non-Hodgkin lymphoma (B-NHL) are recognized in the most recent World Health Organization classification of 2016. The current treatment paradigm, however, is largely based on ‘one-size-fits-all’ immune-chemotherapy. Unfortunately, this therapeutic strategy is inadequat...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groen, Ruben A.L., Schrader, Anne M.R., Kersten, Marie José, Pals, Steven T., Vermaat, Joost S.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959184/
https://www.ncbi.nlm.nih.gov/pubmed/31699794
http://dx.doi.org/10.3324/haematol.2019.227272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959184/
https://www.ncbi.nlm.nih.gov/pubmed/31699794
http://dx.doi.org/10.3324/haematol.2019.227272

Ejemplares similares